Tech Center 1600 • Art Units: 1656
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17264340 | NOVEL CRISPR ENZYMES AND SYSTEMS | Non-Final OA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 16756134 | SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING | Non-Final OA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 19071264 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | Non-Final OA | Halozyme, Inc. |
| 18027461 | Improved Combination of Protease and Protease Inhibitor with Secondary Enzyme | Non-Final OA | BASF SE |
| 18178360 | STORAGE-STABLE LIQUID DETERGENT OR CLEANING AGENT CONTAINING PROTEASE AND LIPASE | Final Rejection | BASF SE |
| 17424824 | METHOD FOR PRODUCTION OF 4-CYANO BENZOIC ACID OR SALTS THEREOF | Final Rejection | BASF SE |
| 18325455 | DISHWASHING DETERGENT COMPOSITION COMPRISING XYLANASE AND SULPHONATED CARBOXYLATE POLYMER | Non-Final OA | The Procter & Gamble Company |
| 18297302 | CLEANING COMPOSITIONS CONTAINING ALGINATE LYASE ENZYMES | Final Rejection | The Procter & Gamble Company |
| 18065641 | HOME CARE COMPOSITION COMPRISING AN AMYLASE | Final Rejection | The Procter & Gamble Company |
| 17310191 | PLATFORM FOR PRODUCING GLYCOPROTEINS, IDENTIFYING GLYCOSYLATION PATHWAYS | Non-Final OA | Northwestern University |
| 17334055 | MINIMAL PEPTIDE FUSIONS FOR TARGETED INTRACELLULAR PROTEIN DEGRADATION | Final Rejection | Massachusetts Institute of Technology |
| 18015752 | AMYLASE-CONTAINING CLEANING AGENT COMPOSITION | Final Rejection | KAO CORPORATION |
| 19041627 | NOVEL RECOMBINANT FACTOR C AND METHOD FOR PRODUCING THE SAME, AND METHOD FOR MEASURING ENDOTOXIN | Non-Final OA | SEIKAGAKU CORPORATION |
| 18490032 | STRAIN WITH IMPROVED AROMATIC AMINO ACID PRODUCTION CAPACITY BY ANSB GENE INACTIVATION | Final Rejection | DAESANG CORPORATION |
| 17291656 | PORE | Non-Final OA | Vrije Universiteit Brussel |
| 18318442 | DETERGENT COMPOSITION COMPRISING LACCASE | Non-Final OA | Novozymes A/S |
| 18318470 | Detergent Composition Comprising Laccase | Non-Final OA | Novozymes A/S |
| 18497253 | YEAST CELLS HAVING REDUCTIVE TCA PATHWAY FROM PYRUVATE TO SUCCINATE AND OVEREXPRESSING AN EXOGENOUS NAD(P+) TRANSHYDROGENASE ENZYME | Non-Final OA | CARGILL, INCORPORATED |
| 17295198 | METHOD FOR THE PRODUCTION OF ENZYMES BY A STRAIN BELONGING TO A FILAMENTOUS FUNGUS | Final Rejection | IFP Energies nouvelles |
| 17968818 | PROTEIN COMPOSITION WITH ISOPRENE POLYMERIZATION ACTIVITY AND APPLICATION THEREOF | Final Rejection | Sumitomo Riko Company Limited |
| 18257311 | ENZYMES AND ENZYME COMPOSITIONS FOR CLEANING | Non-Final OA | DANISCO US INC |
| 17963122 | METHODS OF TREATMENT AND NOVEL CONSTRUCTS | Final Rejection | AUCKLAND UNISERVICES LIMITED |
| 18539833 | METHOD FOR CONVERTING NUCLEIC ACID SEQUENCE OF CELL SPECIFICALLY CONVERTING NUCLEIC ACID BASE OF TARGETED DNA USING CELL ENDOGENOUS DNA MODIFYING ENZYME, AND MOLECULAR COMPLEX USED THEREIN | Final Rejection | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY |
| 17792011 | GENETICALLY MODIFIED BACTERIUM WITH ALTERED ENVELOP INTEGRITY AND USES THEREOF | Non-Final OA | UNIVERSITÉ CATHOLIQUE DE LOUVAIN |
| 17838741 | Recombinant Alpha-Galactosidase A For Treatment Of Fabry Disease | Non-Final OA | Amicus Therapeutics, Inc. |
| 17720006 | FLAVONOID AND ANTHOCYANIN BIOPRODUCTION USING MICROORGANISM HOSTS | Non-Final OA | DEBUT BIOTECHNOLOGY, INC. |
| 16645072 | PHARMACEUTICALS AND DEVICES FOR THE COVALENT IMMOBILIZATION TO THE EXTRACELLULAR MATRIX BY TRANSGLUTAMINASE | Non-Final OA | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG |
| 16483574 | BIOLOGICAL SAMPLE AND BIOLOGICAL INSTRUMENT CLEANLINESS MEASUREMENT KIT AND METHOD | Final Rejection | KIKKOMAN CORPORATION |
| 18449736 | Bacillus Subtilis SK01 and its Application in Plastic Degradation | Non-Final OA | Bijie Shangkun plastic products Co., Ltd |
| 18231468 | METHOD FOR THE PREPARATION OF GELATIN HYDROLYSATE HAVING A LOW ENDOTOXIN CONTENT | Final Rejection | Rousselot BVBA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy